

## Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

Marko Škrtić<sup>1</sup> · Gary K. Yang<sup>1</sup> · Bruce A. Perkins<sup>2</sup> · Nima Soleymanlou<sup>3</sup> · Yuliya Lytvyn<sup>1</sup> · Maximilian von Eynatten<sup>4</sup> · Hans J. Woerle<sup>5</sup> · Odd Erik Johansen<sup>6</sup> · Uli C. Broedl<sup>5</sup> · Thomas Hach<sup>5</sup> · Melvin Silverman<sup>1</sup> · David Z. I. Cherney<sup>1</sup>

Published online: 3 April 2017  
© Springer-Verlag Berlin Heidelberg 2017

**Erratum to: Diabetologia**  
**DOI 10.1007/s00125-014-3396-4**

The authors wish to point out a typographical error in the penultimate paragraph of this research letter. The second main observation of the research was that treatment with empagliflozin for 8 weeks *increased*  $R_A$  (not decreased).

Unfortunately, the *x*-axes for Fig. 1a–d were labelled incorrectly and did not distinguish between participants with normofiltration (T1D-N) or hyperfiltration (T1D-H); the corrected figure is shown overleaf:

---

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-014-3396-4>

---

✉ David Z. I. Cherney  
david.cherney@uhn.on.ca

<sup>1</sup> Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, 585 University Ave, 8N-845, Toronto, ON, Canada M5G 2N2

<sup>2</sup> Department of Medicine, Division of Endocrinology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

<sup>3</sup> Boehringer Ingelheim Canada, Burlington, ON, Canada

<sup>4</sup> Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA

<sup>5</sup> Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany

<sup>6</sup> Boehringer Ingelheim Norway KS, Asker, Norway

